Serum Hevylite
AL Amyloidosis
Hevylite assay
MGUS
light chain
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
23
10
2020
received:
07
08
2020
accepted:
01
11
2020
pubmed:
18
1
2021
medline:
16
6
2021
entrez:
17
1
2021
Statut:
ppublish
Résumé
AL amyloidosis (AL) is a malignant form of plasma cell dyscrasia (PCD). It is insidious, and its end-organ damage can mimic that of common diseases. At diagnosis, routine tests for monoclonal protein are insufficient for the differential diagnosis. We hypothesized that Hevylite Serum samples of patients with a high clinical suspicion of AL were prospectively tested for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ concentrations and ratios using Hevylite Of the 99 samples analyzed, 46 were newly diagnosed AL, and the majority, 38 (82.6%), presented with suppression of at least one HLC isotype. Of the 53 benign PCD patients, 36 (67.9%) presented with elevation of at least one HLC isotype. By multivariate analysis, Hevylite Hevylite
Substances chimiques
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
418-425Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology. 2012;2012:595-603.
Agarwal A, Ghobrial I. Monoclonal gammopathy of undetermined significance and Smoldering Multiple Myeloma: A review of the current understanding of epidemiology, biology, risk stratification and management of myeloma precursor disease. Clin Cancer Res. 2013;19(5):985-994.
Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525-532.
Desport E, Bridoux F, Sirac C, et al. Al amyloidosis. Orphanet J Rare Dis. 2012;7:54.
Graziani MS, Merlini G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Exp Rev Mol Diagn. 2014;14(1):55-66.
Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014;51(Pt 5):528-542.
Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-1933.
Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124-5130.
Gatt ME, Kaplan B, Yogev D, et al. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. Br J Haematol. 2018;182(1):86-92.
Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127.
Prokaeva T, Spencer B, Sun F, et al. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid. 2016;23(4):214-220.
Ermak N, Nguyen-Khoa T, Alyanakian MA. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia. Ann Biol Clin. 2016;74(5):597-605.
Site TB. Serum Free Light Chain Analysis plus Heavylite (7th edn). In: Birmingham, UK: The Binding Site Group Ltd.; 2015.
Gagliardi A, Carbone C, Russo A, et al. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncol Lett. 2016;12(4):2363-2370.
Scudla V, Lochman P, Pika T, Zapletalova J, Minarik J, Bacovsky J. Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis. Cas Lek Ces. 2015;154(6):292-302.
Katzmann JA, Clark R, Kyle RA, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. 2013;27(1):208-212.
Magnano L, Fernandez de Larrea C, Elena M, et al. Prognostic impact of serum heavy/light chain pairs in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma: long-term results from a single institution. Clin Lymphoma Myeloma Leuk. 2016;16(6):e71-77.
Sachchithanantham S, Berlanga O, Alvi A, et al. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis. Br J Haematol. 2017;179(4):575-585.
Katzmann JA, Willrich MA, Kohlhagen MC, et al. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. Clin Chem. 2015;61(2):360-367.
Michallet M, Chapuis-Cellier C, Dejoie T, et al. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia. 2018;32(2):376-382.
Harutyunyan NM, Vardanyan S, Ghermezi M, et al. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol. 2016;174(1):81-87.
Muchtar E, Dispenzieri A, Kumar SK, et al. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016;101(9):1102-1109.
Boyle E, Manier S, Lejeune J, et al. IgMkappa and IgMlambda Measurements for the Assessment of Patients with Waldenstrom's Macroglobulinaemia. Clin Cancer Res. 2016;22(20):5152-5158.
Bradwell AR, Harding SJ, Fourrier NJ, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem. 2009;55(9):1646-1655.
Muchtar E, Dispenzieri A, Kumar SK, et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia. 2017;31(1):92-99.
Andrade-Campos M, Murillo-Florez I, Garcia-Sanz R, Giraldo P. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. Clin Chem Lab Med. 2017;55(10):1598-1604.
Lavatelli F, Albertini R, Di Fonzo A, Palladini G, Merlini G. Biochemical markers in early diagnosis and management of systemic amyloidoses. Clin Chem Lab Med. 2014;52(11):1517-1531.
Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol. 2016;29(2):241-248.
Kraj M. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite) assays for diagnosing and monitoring monoclonal gammopathies. Adv Clin Exp Med. 2014;23(1):127-133.
Hassoun H, Ruiz R, Kazunori M, et al. Comparison of Standard Assays (Serum Immunofixation and Protein Electrophoresis) with Hevylite Assay in Patients with. Multiple Myeloma. 2016;128(22):5626.
Lakomy D, Lemaire-Ewing S, Denimal D, Bastie JN, Lafon I, Caillot D. Evaluation of the new Hevylite IgA assay for the diagnosis and follow-up of monoclonal gammopathies. Ann Biol Clin. 2013;71(2):157-163.